Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy

BACKGROUND: The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) who progress on nonsteroidal aromatase inhibitor (NSAI) therapy. However, none of the patients enrolled in the trial that led...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Cook, Madeline M., Al Rabadi, Luai, Kaempf, Andy J., Saraceni, Megan M., Savin, Michael A., Mitri, Zahi I.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2020
Schlagworte:
Breast Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873317/
https://ncbi.nlm.nih.gov/pubmed/33230905
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13609
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge